FDA grants Emergency Use Authorization for next-generation Covid-19 assays
Thermo Fisher’s kits leverage an updated design from the original TaqPath assays, targeting eight different genes across three regions of the virus that causes Covid-19
Thermo Fisher’s kits leverage an updated design from the original TaqPath assays, targeting eight different genes across three regions of the virus that causes Covid-19
The data suggest that a booster dose given within 6 to 12 months after the second dose may help maintain a high level of protection against COVID-19.
Purchase price of US $ 1.5 billion upfront and up to USD 500 million in success-based milestone payments
The companies anticipate clinical studies to begin in August, subject to regulatory approvals
Subscribe To Our Newsletter & Stay Updated